Ranbaxy Pharmaceuticals Receives FDA Approval for Generic Version of GlaxoSmithKline's Valtrex
February 2, 2007
The Food and Drug Administration has approved a generic form of Valtrex (valacyclovir hydrochloride), GlaxoSmithKline's treatment for genital herpes and shingles, Indian generics maker Ranbaxy Laboratories Ltd. announced Thursday. The approved doses are for 500-mg and 1-gram caplets, the firm said. On Wednesday, Mylan Laboratories received tentative approval of its own 500-mg and 1,000-mg generic versions of Valtrex; however, the company cannot yet market its products due to outstanding patent issues. Patent issues for Mylan will resolve when patents begin to expire June 2009.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.